Bind Biosciences, Inc.: Series C $11M

Posted in I - Series C, Q - 1Q10, R - NORTH EAST, X - Oncology, X - THx Delivery, X - Therapeutic Platform, XX - MA

Bind Biosciences (Cambridge, MA) a preclinical-stage biopharmaceutical company focused on differential medicinal nanoengineered delivery of targeted therapeutics and controlled drug exposure to diseased tissue for various cancers, closed an $11M Series C financing. Participants have included DHK Investments, ARCH Venture Partners, Flagship Ventures, NanoDimension and Polaris Venture Partners.

Feb

2010

EyeGate Pharma, Inc.: Series D $22.6M

Posted in I - Series D, Q - 1Q10, R - NORTH EAST, X - Opthalmology, X - THx Delivery, XX - MA

EyeGate Pharma (Wlatham, MA) a clinical-stage company focused on a non-invasive iontophoresis drug delivery system for ocular therapeutics, closed a $22.6M Series D financing. Participants include Natixis Private Equity, Emerging Capital, Ventech, Innoven Partners and Medicis Capital.

Jan

2010

Terapio Corp.: Series A $5M

Posted in I - Series A, Q - 4Q09, R - SOUTH WEST, X - Radiodermatitis, X - THx Delivery

Terapio (Austin, TX) a preclinical-stage biopharmaceutical company focused on radiodermatitis, closed a $5M Series A financing. Participants have included Santé Ventures and Texas Emerging Technology Fund.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Apr

2009

Traversa Therapeutics, Inc.: Series B $5M

Posted in I - Series B, Q - 2Q09, R - WEST, X - Device (Delivery), X - RNAi, X - THx Delivery, XX - CA

Traversa Therapeutics (La Jolla, CA) a preclinical-stage biopharmaceutical company developing RNAi delivery technologies, closed a $5M Series B financing. Participants include Morningside, Mesa Verde Venture Partners and Tech Coast Angels.

to top of page...